Skip to main content
OpenTrials
Completed

NCT Number: NCT01635959

Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt

The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Patients With Upper Gastro-intestinal Symptoms Deglutition Disorders Digestive System Diseases Esophageal Diseases Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Al Mansurah, Egypt

Loading trial locations.

About this study

Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years and above
  • Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting.

Exclusion criteria

  • Participating on a clinical trial during the last 3 months.
  • Patients not able to read and/or understand the GERD-Q questionnaire.
  • Patients already included in the study in other participating site.
  • Patients taking PPIs or H2blockers in the l

Treatment and study plan

Primary outcomes

  1. Percentage of patients scoring ≥ 8 in GERD-Q

    Time frame: baseline

    Percentage of patients scoring ≥ 8 in GERD-Q will be considered as suffering from GERD.

    The GERD-Q is a potentially useful tool for family practitioners and other health care professionals in diagnosing and managing GERD without initial specialist referral or endoscopy.

    The Egyptian-validated version of the GERD-Q will be used for the study purposes.

Secondary outcomes

  1. Socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD)

    Time frame: baseline

    Descriptive analysis of socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD) in Egypt.

  2. Treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD)

    Time frame: baseline

    Descriptive analysis of treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD) in Egypt.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: GERD Q NIS

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Jul 10, 2012
Registry last updated
Oct 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.